Literature DB >> 14688525

Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro.

Roman A Blaheta1, Harilaos Bogossian, Wolf-Dietrich Beecken, Dietger Jonas, Christoph Hasenberg, Jasmina Makarevic, Henry Ogbomo, Wolf O Bechstein, Elsie Oppermann, Kerstin Leckel, Jindrich Cinatl.   

Abstract

BACKGROUND: The immunosuppressive drug mycophenolate mofetil (MMF) reduces expression of the heterophilic binding elements intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and thereby prevents attachment of alloactivated leukocytes to donor endothelium. The authors speculated that MMF might further diminish receptors of the immunoglobulin superfamily which, however, act as homophilic binding elements. Because decrease of homophilic adhesion receptors correlates with tumor dissemination and metastasis, MMF could trigger development or recurrence of neoplastic tumors.
METHODS: The authors analyzed the influence of MMF on homotypic adhesion receptors and its consequence for tumor cell attachment to an endothelial cell monolayer. Neuroblastoma (NB) cells, which self-aggregate by means of the homophilic-binding element neural cell adhesion molecule (NCAM), were used. Effects of MMF on the 140- and 180-kDa NCAM isoforms were investigated quantitatively by flow cytometry, Western blot, and reverse-transcriptase (RT) polymerase chain reaction (PCR). The relevance of NCAM for tumor cell binding was proven by treating NB with NCAM antisense oligonucleotides.
RESULTS: MMF profoundly increased the number of adherent NB cells, with a maximum effect at 0.1 microM, compared with controls. Decrease of NCAM on the cell surface was detected by flow cytometry. Western blot and RT-PCR demonstrated reduced protein and RNA levels of the 140- and 180-kDa isoforms. Treatment of NB cells with NCAM antisense oligonucleotides showed that reduced NCAM expression leads to enhanced tumor cell adhesion.
CONCLUSIONS: MMF decreases NCAM receptors, which is associated with enhanced tumor cell invasiveness. The authors conclude that an MMF-based immunosuppressive regimen might increase the risk of tumor metastasis if this process is predominantly conveyed by means of homophilic adhesion proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688525     DOI: 10.1097/01.TP.0000092004.83992.B2

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  [Research in urologic university clinics. Assessment of current status and perspectives].

Authors:  K Miller; H Krause
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  Risk factors and outcomes for the development of malignancy in lung and heart-lung transplant recipients.

Authors:  Michael J Metcalfe; Demetrios J Kutsogiannis; Kathy Jackson; Antigone Oreopoulous; John Mullen; Denis Modry; Justin Weinkauf; Dale C Lien; Ken C Stewart
Journal:  Can Respir J       Date:  2010 Jan-Feb       Impact factor: 2.409

Review 3.  Malignancy in kidney transplant recipients.

Authors:  Anil Kapoor
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Management and prevention of post-transplant malignancies in kidney transplant recipients.

Authors:  Giovanni Stallone; Barbara Infante; Giuseppe Grandaliano
Journal:  Clin Kidney J       Date:  2015-07-23

6.  Mycophenolate Mofetil induces c-Jun-N-terminal kinase expression in 22Rv1 cells: an impact on androgen receptor signaling.

Authors:  Ondrej Zenata; Zdenek Dvorak; Radim Vrzal
Journal:  J Cancer       Date:  2018-04-27       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.